BEAM

Beam Therapeutics (BEAM) shares surged 15.6% following positive early-stage data for its experimental gene-editing treatment BEAM-301 for glycogen storage disease type Ia. The treatment showed improvements in fasting tolerance and glucose control in six patients, with two patients no longer requiring daily starch supplements.

Despite some serious adverse events, the company plans to test higher doses and pursue FDA approval discussions. However, earnings estimate revisions remain unchanged, which may limit sustained momentum.

Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.